MHC-Ig Dimers: The next Frontier in Transplantation Immunology

Authors

  • Ronald Nyarambe Wigina Technical University of Mombasa, Department of Medical Sciences
  • Victor Tunje Jeza Huangzhong University of Science and Technology, Tongji Medical College, Department of Immunology Technical University of Mombasa, Department of Medical Science

DOI:

https://doi.org/10.7439/ijbr.v6i9.2327

Keywords:

Aplastic Anaemic, rural population, Bidar District, Clinical profile haematological profile, aetiological factor.

Abstract

Organ transplantation offers hope to a variety of patients with terminal functioning organs and tissues. This is currently made possible by administration of general immunosuppressive drugs. To date, inducing tolerance to allografts has become the holy grail of every transplantation immunologist. In effect, there has been a great deal of research aiming to come up with alternative therapeutic mechanisms that would allow one to do away with or reduce the amount of general immunosuppressive drugs used either at the induction, maintenance, or both phases. It has been shown in recent years that MHC-Ig dimers can induce suppression of alloresponsive T cells in a donor specific fashion. Consequently, MHC-Ig fusion proteins are currently forming the next field for exploitation which is great progress in transplantation immunology since the discovery of the first immunosuppressive drugs in terms of inducing tolerance to transplanted organs and tissues. This review aims to discuss this progress.

Downloads

Download data is not yet available.

Author Biographies

  • Ronald Nyarambe Wigina, Technical University of Mombasa, Department of Medical Sciences

    Medical Sciences

    Lecturer

  • Victor Tunje Jeza, Huangzhong University of Science and Technology, Tongji Medical College, Department of Immunology Technical University of Mombasa, Department of Medical Science

    Medical Science Department

    Lecturer

Downloads

Published

2015-09-30

Issue

Vol. 6 No. 9 (2015): Sep

Section

Review Article

License

Authors who publish with this journal agree to the following terms:

  • Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
  • Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
  • Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).
  • An author must submit Copyright form After acceptance of the article.

How to Cite

1.
MHC-Ig Dimers: The next Frontier in Transplantation Immunology. Int Jour of Biomed Res [Internet]. 2015 Sep. 30 [cited 2025 Mar. 12];6(9):601-1. Available from: https://ssjournals.co.in/index.php/ijbr/article/view/2327